Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company - STAA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company - STAA

Canada NewsWire

NEW YORK, May 9, 2019 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether STAAR and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action] 

On May 3, 2019, STAAR disclosed receipt of a letter from the Center for Devices and Radiological Health of the U.S. Food and Drug Administration ("FDA") regarding its review of the Company's premarket approval application ("PMA") supplement regarding EVO/EVO+ Visian Implantable Collamer Lens for Myopia and EVO/EVO+ Visian Toric Implantable Collamer Lens for Myopia with Astigmatism.  In the letter, the FDA specifically "advised the Company that its PMA supplement lacked information, particularly the clinical evidence and analysis, that would permit the completion of the review and determination of whether there is a reasonable assurance of the device's safety and effectiveness for its intended use." 

On this news, STAAR's stock price fell $3.15 per share, or 11.19%, to close at $25.00 per share on May 3, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-staar-surgical-company---staa-300847732.html

SOURCE Pomerantz LLP

View original content: http://www.newswire.ca/en/releases/archive/May2019/09/c7528.html

Copyright CNW Group 2019

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today